Stifel Financial Corp Has $292.20 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

by · The Markets Daily

https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&h=150&zc=2&src=https://www.marketbeat.com/logos/amgen-inc-logo.jpg
Stifel Financial Corp grew its position in Amgen Inc. (NASDAQ:AMGN – Free Report) by 2.6% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,316,001 shares of the medical research company’s stock after acquiring an additional 33,325 shares during the period. Stifel Financial Corp owned 0.25% of Amgen worth $292,204,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Bank Julius Baer & Co. Ltd Zurich lifted its position in Amgen by 99,178.6% during the 2nd quarter. Bank Julius Baer & Co. Ltd Zurich now owns 309,188,418 shares of the medical research company’s stock worth $68,646,013,000 after buying an additional 308,876,983 shares in the last quarter. Moneta Group Investment Advisors LLC raised its stake in shares of Amgen by 83,875.6% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 7,541,011 shares of the medical research company’s stock worth $1,980,571,000 after acquiring an additional 7,532,031 shares during the last quarter. Norges Bank acquired a new position in shares of Amgen during the fourth quarter valued at $1,351,778,000. Envestnet Asset Management Inc. increased its position in Amgen by 216.1% in the first quarter. Envestnet Asset Management Inc. now owns 2,690,718 shares of the medical research company’s stock worth $228,997,000 after purchasing an additional 1,839,455 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its holdings in Amgen by 158.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,950,013 shares of the medical research company’s stock worth $774,791,000 after purchasing an additional 1,806,456 shares during the last quarter. Institutional investors own 74.44% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently commented on AMGN. Leerink Partnrs raised Amgen from a “market perform” rating to an “outperform” rating in a research note on Wednesday, October 11th. Deutsche Bank Aktiengesellschaft started coverage on Amgen in a report on Thursday, November 9th. They set a “hold” rating and a $240.00 price objective on the stock. JPMorgan Chase & Co. restated a “neutral” rating and set a $270.00 target price on shares of Amgen in a report on Friday, October 20th. Barclays raised their price objective on shares of Amgen from $210.00 to $230.00 in a report on Monday, October 2nd. Finally, Truist Financial restated a “buy” rating and issued a $320.00 target price on shares of Amgen in a research note on Wednesday, November 29th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $280.35.

View Our Latest Research Report on AMGN

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 2,096 shares of the company’s stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $273.03, for a total value of $572,270.88. Following the completion of the transaction, the senior vice president now directly owns 10,874 shares in the company, valued at approximately $2,968,928.22. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, EVP Jonathan P. Graham sold 10,000 shares of the business’s stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $272.81, for a total transaction of $2,728,100.00. Following the transaction, the executive vice president now owns 28,078 shares in the company, valued at approximately $7,659,959.18. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Nancy A. Grygiel sold 2,096 shares of the stock in a transaction on Monday, December 4th. The stock was sold at an average price of $273.03, for a total transaction of $572,270.88. Following the transaction, the senior vice president now directly owns 10,874 shares in the company, valued at $2,968,928.22. The disclosure for this sale can be found here. 0.46% of the stock is owned by insiders.

Amgen Stock Up 1.1 %

AMGN opened at $272.14 on Tuesday. The stock has a fifty day moving average of $270.34 and a 200-day moving average of $251.90. The company has a market capitalization of $145.64 billion, a P/E ratio of 19.34, a P/E/G ratio of 2.57 and a beta of 0.58. Amgen Inc. has a fifty-two week low of $211.71 and a fifty-two week high of $288.46. The company has a debt-to-equity ratio of 7.71, a quick ratio of 2.56 and a current ratio of 2.86.

Amgen (NASDAQ:AMGN – Get Free Report) last announced its earnings results on Tuesday, October 31st. The medical research company reported $4.96 EPS for the quarter, topping the consensus estimate of $4.65 by $0.31. Amgen had a net margin of 28.20% and a return on equity of 165.37%. The company had revenue of $6.90 billion for the quarter, compared to analysts’ expectations of $6.92 billion. During the same period last year, the firm earned $4.70 earnings per share. The business’s revenue for the quarter was up 3.7% on a year-over-year basis. On average, equities analysts expect that Amgen Inc. will post 18.62 EPS for the current year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, December 8th. Shareholders of record on Friday, November 17th were issued a $2.13 dividend. This represents a $8.52 dividend on an annualized basis and a dividend yield of 3.13%. The ex-dividend date of this dividend was Thursday, November 16th. Amgen’s dividend payout ratio is presently 60.55%.

Amgen Profile

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.

Featured Articles